Novartis gets boost from an unexpected source—Alcon—as generic pricing sinks Sandoz sales
admin 18th July 2017 Uncategorised 0Two words and an exclamation point summed up Novartis’ second-quarter earnings surprise: “Alcon grew (!),” declared Bernstein analyst Tim Anderson. The drugmaker needed that unexpected boost from its struggling eye business, because generics price erosion took a bite out of its copycat drug business Sandoz.
More: Novartis gets boost from an unexpected source—Alcon—as generic pricing sinks Sandoz sales
Source: fierce